The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic significance of bone metastases (BM) and bisphosphonate (BIS) therapy in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs).
Rana R. McKay
Consultant or Advisory Role - Pfizer (U)
Xun Lin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Julia Jane Perkins
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ronit Simantov
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Toni K. Choueiri
Consultant or Advisory Role - Pfizer